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The biopharmaceutical industry strives to develop and operate efficient, robust, reproducible commercial 
biologics processes.  A major challenge of industrial biologics processes is optimization of cell culture conditions 
to increase productivity while maintaining consistent product quality.  The cell culture operations, which involve 
the use of live cell hosts, have historically introduced significant variability to the overall process.  Technological 
improvements which include the implementation of advanced cell line engineering, chemically defined media, 
quality by design (QbD) development approaches, and in-line and at-line monitoring, have significantly reduced 
process variability.  Nonetheless, performance variability remains a challenge for many commercial programs.  
This variability in turn can impact both product yields and product quality.  Even small performance differences 
can become significant in low-yield processes with large campaign sizes, or processes manufactured at multiple 
sites.  The ability to understand and eliminate sources of variability is greatly enhanced by augmenting the 
quality and quantity of data available from commercial campaigns. 
 
Metabolomics Process Monitoring (MPM) is a data-driven approach to understand sources of manufacturing 
variability on a cellular level.  Here we present a case study of MPM implementation in a legacy commercial 
biologics program.  First, we describe how the MPM workflow was successfully integrated into a commercial 
manufacturing process.  Second, we discuss novel data normalization techniques developed to enable long 
term trending.  Third, we describe the selection of an orthogonal projections to latent structures (OPLS) model to 
link systems biology and process data.  Finally, we share key mechanistic insights obtained from the case study, 
and provide a vision for how MPM can enhance commercial biologics capabilities going forward. 
 
 
